Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis
- 20 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 33 (1) , 65-74
Abstract
Background: Low-dose glucocorticoids are commonly used in the treatment of rheumatoid arthritis (RA). Observational studies have found an increased risk of serious infection associated with low-dose glucocorticoids, but concerns about residual confounding remain. Methods: We identified adults with RA on stable immunomodulatory therapy for >6 months receiving no glucocorticoids or ≤5 mg/day using Medicare data from 2006 to 2015. We used provider preference for glucocorticoids as an instrumental variable (IV) to assess associations between low-dose glucocorticoid use and the risk of infection requiring hospitalization using a cause-specific proportional hazards model. Results: We identified 163,603 qualifying treatment episodes among 120,656 patients. Glucocorticoids ≤5 mg/day were used by 25,373/81,802 (31.0%) of patients seen by a rheumatologist with low provider preference for glucocorticoids and by 36,087/81,801 (44.1%) of patients seen by a rheumatologist with high provider preference for glucocorticoids (adjusted odds ratio 1.81, 95% confidence interval 1.77, 1.84 for association between provider preference and glucocorticoids). Chronic obstructive pulmonary disease, opioids, antibiotics, previous emergency department visits, hospitalizations, and infections requiring hospitalization infections were unbalanced with regard to exposure but not to the IV. The incidence of infection requiring hospitalization was 8.0/100 person–years among patients unexposed to glucocorticoids versus 11.7/100 person–years among those exposed. The association between glucocorticoids and infection requiring hospitalization from IV analysis (hazard ratio 1.26 [1.02–1.56]) was similar to results from a standard multivariable model (hazard ratio 1.24 [1.21–1.28]). Conclusions: Among patients with RA on stable immunomodulatory therapy, IV analysis based on provider preference demonstrated an increased risk of infection requiring hospitalization associated with low-dose glucocorticoids, similar to a traditional analysis.Keywords
This publication has 36 references indexed in Scilit:
- Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)Annals of the Rheumatic Diseases, 2013
- Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysisAnnals of the Rheumatic Diseases, 2012
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practiceArthritis Care & Research, 2011
- A combined comorbidity score predicted mortality in elderly patients better than existing scoresJournal of Clinical Epidemiology, 2011
- Validation of rheumatoid arthritis diagnoses in health care utilization dataArthritis Research & Therapy, 2011
- Instrumental variable methods in comparative safety and effectiveness researchPharmacoepidemiology and Drug Safety, 2010
- The Hazards of Hazard RatiosEpidemiology, 2010
- Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental VariableEpidemiology, 2006
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005